Common vitamin may help repair liver damage caused by disease

Researchers have found that a daily 300 mg dose of vitamin E improves liver tissue in adults with metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease where fat buildup triggers inflammation and damage in the liver.

The result reframes a common supplement as a potential way to ease damage in a disease that often advances without symptoms.

Vitamin E and liver damage

Across biopsy samples taken before and after treatment, injured liver tissue showed measurable recovery in people receiving vitamin E. 

Working across multiple clinical centers, Junping Shi at Hangzhou Normal University (HZNU) documented these changes as they appeared directly in patient tissue. 

Improvement occurred in about 29.3% of treated participants compared with 14.1% given a placebo over the same period. 

The gap points to a real biological effect while leaving open how broadly and reliably the benefit will hold in larger populations.

Why dose matters

Earlier vitamin E studies usually tested higher amounts, so this trial asked whether a smaller daily dose could still help.

In the 2010 study, 800 IU a day improved liver disease in 43% of treated adults without diabetes.

This newer trial used 300 milligrams a day instead, and it still improved fat buildup, inflammation, and fibrosis, the scarring that makes the liver stiff.

Because treatment for MASH often lasts a long time, a meta-analysis found benefits but uneven fibrosis results.

What MASH does

MASH begins when fat piles up in the liver and the organ becomes inflamed enough to start losing healthy cells.

Unlike simple fatty liver, this form can lay down scar tissue that makes the organ harder and less able to do its work.

Cases have climbed with obesity and type 2 diabetes, and a recent review shows the rise is still underway worldwide.

Once scarring advances too far, the risks of cirrhosis, liver cancer, and transplant rise sharply.

How vitamin E works on liver cells

Vitamin E works as an antioxidant, soaking up unstable molecules before they keep damaging cell membranes and feeding inflammation.

As that pressure eases, fewer liver cells swell and blood markers of injury can start to fall.

Blood tests that usually rise when the liver is irritated dropped more in the vitamin E group, and one inflammation marker fell too.

Food still matters too, with nuts, seeds, and vegetable oils supplying the same nutrient in ordinary diets.

Signals beyond tissue

Doctors did not rely only on tissue slides to judge what changed during treatment. Noninvasive stiffness scans also moved in a better direction, suggesting the liver became a little less rigid over time.

That matters because a stiff liver often reflects deeper scarring, even when a patient feels perfectly well.

The scan result was modest, but it lined up with the tissue findings instead of contradicting them.

Safety has always been the sticking point for vitamin E in liver care. For that reason, the lower dose in this study was more than a small technical detail.

In this study, however, the serious events that occurred were not judged to be caused by treatment.

That cleaner picture is encouraging, but a modest-sized study still leaves room for rare harms to surface later.

Where doctors stand

Current guidance from the American Association for the Study of Liver Diseases limits vitamin E to selected adults without diabetes or cirrhosis.

Lifestyle change remains the base treatment, because weight loss can reduce liver fat and sometimes reverse early damage.

Low-dose vitamin E may fit best as a supervised add-on for non-diabetic adults who match the trial population.

Anyone buying supplements on their own would be guessing, since the wrong dose or the wrong patient can turn a promising idea into a bad plan.

Limits of this trial

COVID disruptions pushed more people out of the study than the researchers had expected.

All 14 centers were in China, and every participant had MASH confirmed with a liver tissue sample before treatment began.

Those facts strengthen the tissue data but also narrow who the results can fairly describe.

People with diabetes, cirrhosis, or very different diets and genetics may not respond the same way.

Why this matters

Even with growing attention, MASH care is still expensive, uneven, and often delayed until scarring is already present.

A vitamin that is familiar, widely available, and already part of ordinary diets would be easier to study and easier to reach.

That practical advantage makes this lower-dose result worth taking seriously, especially in places with fewer specialty liver clinics.

Cost and access do not prove efficacy, but they help explain why this result has drawn so much attention.

The new trial does not settle vitamin E’s place in MASH, but it strengthens the case that some liver damage can improve with a simpler treatment.

Larger studies in more diverse patients now need to show who benefits most, how long the benefit lasts, and how this vitamin fits alongside diet, weight loss, and prescription treatment.

The study is published in Cell Reports Medicine.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–